Filing Details
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) filed a Form 8-K with the Securities and Exchange Commission on October 27, 2026, disclosing a material event.
8k filedNASDAQ:ARTV
Artiva Biotherapeutics, Inc. (ARTV) Reports Material Event to SEC
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) filed a Form 8-K with the Securities and Exchange Commission on October 27, 2026, disclosing a material event.
At publication ·
What changed
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Artiva Biotherapeutics filed a Form 8-K with the SEC on October 27, 2026, disclosing a material event requiring shareholder disclosure.
- The company's stock trades at $4.27 with a market capitalization of $142.9 million.
- Form 8-K filings report material events such as leadership changes, acquisitions, asset sales, or guidance changes between regular reports.
Market Context
Artiva Biotherapeutics, Inc.'s stock currently trades at $4.27 with a market capitalization of $142.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Artiva Biotherapeutics, Inc.'s stock.
All SEC filings for Artiva Biotherapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ARTV Stock Page
Frequently Asked Questions
Where can I read ARTV's SEC filings?
Browse all filings on our ARTV SEC filings page.
What types of SEC filings does Artiva Biotherapeutics, Inc. file?
Public companies like Artiva Biotherapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.